Abstract
I found the title of this episode of Controversies in IBD—“Is There Still a Role for Cyclosporine in the Treatment of Inflammatory Bowel Disease? Pro Argument”—a bit perplexing. When did cyclosporine (CSA) ever cease to have a role in inflammatory bowel disease (IBD)? Is one to suppose that the surgery for ulcerative colitis (UC) has become so refined that all patients undergoing surgery for severe colitis are rendered “cured” of their chronic intestinal ailments? Or should we believe that, despite the lack of controlled trial evidence in severe UC, infliximab has already become an acceptable alternative to cyclosporine or surgery? For patients with severe UC who do not benefit from steroid treatment, both randomized controlled trial data and extensive open-label experience demonstrate the consistent efficacy of CSA, albeit at a stiff cost. For patients with the far less frequent Crohn's disease (CD) who do not benefit from any medical therapy, including infliximab, and are confronted with limited surgical options, CSA clearly remains an important option as well.

This publication has 22 references indexed in Scilit: